Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016

Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016
Published Aug 10, 2016
90 pages — Published Aug 10, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016, provides an overview of the Valeant Pharmaceuticals International, Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc.
- The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Valeant Pharmaceuticals International, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Valeant Pharmaceuticals International, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Valeant Pharmaceuticals International, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensi

  
Source:
Document ID
GMDHC08114CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Valeant Pharmaceuticals International, Inc. Snapshot71
  Valeant Pharmaceuticals International, Inc. Overview71
  Key Information71
  Key Facts71
Valeant Pharmaceuticals International, Inc. Research and Development Overview83
  Key Therapeutic Areas83
Valeant Pharmaceuticals International, Inc. Pipeline Review117
  Pipeline Products by Stage of Development111
  Pipeline Products Monotherapy121
  Pipeline Products Combination Treatment Modalities131
  Pipeline Products Partnered Products141
    Partnered Products/Combination Treatment Modalities151
  Pipeline Products Out-Licensed Products161
    Out-Licensed Products/Combination Treatment Modalities171
Valeant Pharmaceuticals International, Inc. Pipeline Products Glance186
  Valeant Pharmaceuticals International, Inc. Late Stage Pipeline Products181
    Pre-Registration Products/Combination Treatment Modalities181
    Phase III Products/Combination Treatment Modalities191
  Valeant Pharmaceuticals International, Inc. Clinical Stage Pipeline Products201
    Phase II Products/Combination Treatment Modalities201
    Phase I Products/Combination Treatment Modalities211
  Valeant Pharmaceuticals International, Inc. Early Stage Pipeline Products221
    Preclinical Products/Combination Treatment Modalities221
  Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products231
    Unknown Products/Combination Treatment Modalities231
Valeant Pharmaceuticals International, Inc. Drug Profiles2434
  brodalumab241
    Product Description241
    Mechanism of Action241
    R&D Progress242
  (halobetasol propionate + tazarotene)261
    Product Description261
    Mechanism of Action261
    R&D Progress261
  budesonide271
    Product Description271
    Mechanism of Action271
    R&D Progress274
  IDP-122311
    Product Description311
    Mechanism of Action311
    R&D Progress311
  loteprednol etabonate next generation321
    Product Description321
    Mechanism of Action321
    R&D Progress321
  rifaximin DR331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  BLO-020341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  ezogabine351
    Product Description351
    Mechanism of Action351
    R&D Progress353
  IDP-120381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  IDP-121391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  IDP-125401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  IDP-126411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  IDP-127421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  IDP-128431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  IDP-129441
    Product Description441
    Mechanism of Action441
    R&D Progress441
  IDP-130451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  IDP-131461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  lapuleucel-T471
    Product Description471
    Mechanism of Action471
    R&D Progress472
  ribavirin491
    Product Description491
    Mechanism of Action491
    R&D Progress491
  SAL-021501
    Product Description501
    Mechanism of Action501
    R&D Progress501
    Product Description511
    Mechanism of Action511
    R&D Progress511
  SPT-201521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  metyrosine531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  BLO-021541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  IDP-123551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  IDP-124561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  VALBRO-03571
    Product Description571
    Mechanism of Action571
    R&D Progress571
Valeant Pharmaceuticals International, Inc. Pipeline Analysis586
  Valeant Pharmaceuticals International, Inc. Pipeline Products by Target582
  Valeant Pharmaceuticals International, Inc. Pipeline Products by Route of Administration601
  Valeant Pharmaceuticals International, Inc. Pipeline Products by Molecule Type611
  Valeant Pharmaceuticals International, Inc. Pipeline Products by Mechanism of Action622
Valeant Pharmaceuticals International, Inc. Recent Pipeline Updates649
Valeant Pharmaceuticals International, Inc. Dormant Projects732
Valeant Pharmaceuticals International, Inc. Discontinued Pipeline Products753
  Discontinued Pipeline Product Profiles751
    ATON-004751
    (bupropion hydrochloride + selective serotonin reuptake inhibitor)751
    brodalumab751
    CVTE-002761
    ezogabine761
    IDP-107761
    IDP-109761
    IDP-115761
    MC-5761
    methylnaltrexone bromide761
    pegaptanib sodium761
    rifaximin761
    RUS-350771
    taribavirin hydrochloride771
    tiazofurin771
    UK-279276771
Valeant Pharmaceuticals International, Inc. Company Statement783
Valeant Pharmaceuticals International, Inc. Locations And Subsidiaries818
  Head Office811
  Other Locations &Subsidiaries818
Appendix892
  Methodology891
  Coverage891
  Secondary Research891
  Primary Research891
  Expert Panel Validation891
  Contact Us891
  Disclaimer901

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Valeant-Pharmaceuticals-International-Inc-Product-Pipeline-Review-2016-2088-16368>
  
APA:
Global Markets Direct - Market Research. (2016). Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Valeant-Pharmaceuticals-International-Inc-Product-Pipeline-Review-2016-2088-16368>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.